Protein Engineering Design & Selection最新文献

筛选
英文 中文
Antibody-mediated delivery of CRISPR-Cas9 ribonucleoproteins in human cells. 抗体介导的 CRISPR-Cas9 核糖核蛋白在人体细胞中的传递。
IF 2.4 4区 生物学
Protein Engineering Design & Selection Pub Date : 2022-02-17 DOI: 10.1093/protein/gzac011
Stephanie Ubiparipovic, Daniel Christ, Romain Rouet
{"title":"Antibody-mediated delivery of CRISPR-Cas9 ribonucleoproteins in human cells.","authors":"Stephanie Ubiparipovic, Daniel Christ, Romain Rouet","doi":"10.1093/protein/gzac011","DOIUrl":"10.1093/protein/gzac011","url":null,"abstract":"<p><p>The CRISPR genome editing technology holds great clinical potential for the treatment of monogenetic disorders such as sickle cell disease. The therapeutic in vivo application of the technology relies on targeted delivery methods of the Cas9 and gRNA complex to specific cells or tissues. However, such methods are currently limited to direct organ delivery, preventing clinical application. Here, we show that monoclonal antibodies can be employed to deliver the Cas9/gRNA complex directly into human cells via cell-surface receptors. Using the SpyCatcher/SpyTag system, we conjugated the Fab fragment of the therapeutic antibodies Trastuzumab and Pertuzumab directly to the Cas9 enzyme and observed HER2-specific uptake of the ribonucleoprotein in a human HER2 expressing cell line. Following cellular uptake in the presence of an endosomolytic peptide, modest gene editing was also observed. This finding provides a blueprint for the targeted delivery of the CRISPR technology into specific cells using monoclonal antibodies.</p>","PeriodicalId":54543,"journal":{"name":"Protein Engineering Design & Selection","volume":"35 ","pages":""},"PeriodicalIF":2.4,"publicationDate":"2022-02-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10385168","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"生物学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 1
Affinity maturation of TCR-like antibodies using phage display guided by structural modeling. 在结构建模指导下利用噬菌体展示技术实现 TCR 类抗体的亲和成熟。
IF 2.6 4区 生物学
Protein Engineering Design & Selection Pub Date : 2022-02-17 DOI: 10.1093/protein/gzac005
Rahel Frick, Lene S Høydahl, Ina Hodnebrug, Erik S Vik, Bjørn Dalhus, Ludvig M Sollid, Jeffrey J Gray, Inger Sandlie, Geir Åge Løset
{"title":"Affinity maturation of TCR-like antibodies using phage display guided by structural modeling.","authors":"Rahel Frick, Lene S Høydahl, Ina Hodnebrug, Erik S Vik, Bjørn Dalhus, Ludvig M Sollid, Jeffrey J Gray, Inger Sandlie, Geir Åge Løset","doi":"10.1093/protein/gzac005","DOIUrl":"10.1093/protein/gzac005","url":null,"abstract":"<p><p>TCR-like antibodies represent a unique type of engineered antibodies with specificity toward pHLA, a ligand normally restricted to the sensitive recognition by T cells. Here, we report a phage display-based sequential development path of such antibodies. The strategy goes from initial lead identification through in silico informed CDR engineering in combination with framework engineering for affinity and thermostability optimization, respectively. The strategy allowed the identification of HLA-DQ2.5 gluten peptide-specific TCR-like antibodies with low picomolar affinity. Our method outlines an efficient and general method for development of this promising class of antibodies, which should facilitate their utility including translation to human therapy.</p>","PeriodicalId":54543,"journal":{"name":"Protein Engineering Design & Selection","volume":"35 ","pages":""},"PeriodicalIF":2.6,"publicationDate":"2022-02-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9536190/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10384397","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"生物学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Modifying pH-sensitive PCSK9/LDLR interactions as a strategy to enhance hepatic cell uptake of low-density lipoprotein cholesterol (LDL-C). 改变ph敏感的PCSK9/LDLR相互作用作为增强肝细胞对低密度脂蛋白胆固醇(LDL-C)摄取的策略
IF 2.4 4区 生物学
Protein Engineering Design & Selection Pub Date : 2022-02-17 DOI: 10.1093/protein/gzab032
Lital Ben-Naim, Isam Khalaila, Niv Papo
{"title":"Modifying pH-sensitive PCSK9/LDLR interactions as a strategy to enhance hepatic cell uptake of low-density lipoprotein cholesterol (LDL-C).","authors":"Lital Ben-Naim,&nbsp;Isam Khalaila,&nbsp;Niv Papo","doi":"10.1093/protein/gzab032","DOIUrl":"https://doi.org/10.1093/protein/gzab032","url":null,"abstract":"<p><p>LDL-receptor (LDLR)-mediated uptake of LDL-C into hepatocytes is impaired by lysosomal degradation of LDLR, which is promoted by proprotein convertase subtilisin/kexin type 9 (PCSK9). Cell surface binding of PCSK9 to LDLR produces a complex that translocates to an endosome, where the acidic pH strengthens the binding affinity of PCSK9 to LDLR, preventing LDLR recycling to the cell membrane. We present a new approach to inhibit PCSK9-mediated LDLR degradation, namely, targeting the PCSK9/LDLR interface with a PCSK9-antagonist, designated Flag-PCSK9PH, which prevents access of WT PCSK9 to LDLR. In HepG2 cells, Flag-PCSK9PH, a truncated version (residues 53-451) of human WT PCSK9, strongly bound LDLR at the neutral pH of the cell surface but dissociated from it in the endosome (acidic pH), allowing LDLR to exit the lysosomes intact and recycle to the cell membrane. Flag-PCSK9PH thus significantly enhanced cell-surface LDLR levels and the ability of LDLR to take up extracellular LDL-C.</p>","PeriodicalId":54543,"journal":{"name":"Protein Engineering Design & Selection","volume":" ","pages":""},"PeriodicalIF":2.4,"publicationDate":"2022-02-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"39638977","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"生物学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 1
Reducing substrate inhibition of malate dehydrogenase from Geobacillus stearothermophilus by C-terminal truncation. c端截断法降低嗜热硬脂地杆菌苹果酸脱氢酶的底物抑制作用。
IF 2.4 4区 生物学
Protein Engineering Design & Selection Pub Date : 2022-02-17 DOI: 10.1093/protein/gzac008
Yuya Shimozawa, Hinano Matsuhisa, Tsutomu Nakamura, Tomoki Himiyama, Yoshiaki Nishiya
{"title":"Reducing substrate inhibition of malate dehydrogenase from Geobacillus stearothermophilus by C-terminal truncation.","authors":"Yuya Shimozawa,&nbsp;Hinano Matsuhisa,&nbsp;Tsutomu Nakamura,&nbsp;Tomoki Himiyama,&nbsp;Yoshiaki Nishiya","doi":"10.1093/protein/gzac008","DOIUrl":"https://doi.org/10.1093/protein/gzac008","url":null,"abstract":"<p><p>Malate dehydrogenase (MDH) catalyzes the reduction of oxaloacetate to L-malate. Geobacillus stearothermophilus MDH (gs-MDH) is used as a diagnostic reagent; however, gs-MDH is robustly inhibited at high substrate concentrations, which limits its reaction rate. Here, we reduced substrate inhibition of gs-MDH by deleting its C-terminal residues. Computational analysis showed that C-terminal residues regulate the position of the active site loop. C-terminal deletions of gs-MDH successfully increased Ki values by 5- to 8-fold with maintained thermal stability (>90% of the wild-type enzyme), although kcat/Km values were decreased by <2-fold. The structure of the mutant showed a shift in the location of the active site loop and a decrease in its volume, suggesting that substrate inhibition was reduced by eliminating the putative substrate binding site causing inhibition. Our results provide an effective method to reduce substrate inhibition of the enzyme without loss of other parameters, including binding and stability constants.</p>","PeriodicalId":54543,"journal":{"name":"Protein Engineering Design & Selection","volume":"35 ","pages":""},"PeriodicalIF":2.4,"publicationDate":"2022-02-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10384924","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"生物学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Protein engineering approach to enhance activity assays of mono-ADP-ribosyltransferases through proximity. 通过蛋白质工程学方法增强单-ADP-核糖转移酶的活性检测。
IF 2.6 4区 生物学
Protein Engineering Design & Selection Pub Date : 2022-02-17 DOI: 10.1093/protein/gzac006
Albert Galera-Prat, Juho Alaviuhkola, Heli I Alanen, Lari Lehtiö
{"title":"Protein engineering approach to enhance activity assays of mono-ADP-ribosyltransferases through proximity.","authors":"Albert Galera-Prat, Juho Alaviuhkola, Heli I Alanen, Lari Lehtiö","doi":"10.1093/protein/gzac006","DOIUrl":"10.1093/protein/gzac006","url":null,"abstract":"<p><p>Human mono-ADP-ribosylating PARP enzymes have been linked to several clinically relevant processes and many of these PARPs have been suggested as potential drug targets. Despite recent advances in the field, efforts to discover inhibitors have been hindered by the lack of tools to rapidly screen for high potency compounds and profile them against the different enzymes. We engineered mono-ART catalytic fragments to be incorporated into a cellulosome-based octavalent scaffold. Compared to the free enzymes, the scaffold-based system results in an improved activity for the tested PARPs due to improved solubility, stability and the proximity of the catalytic domains, altogether boosting their activity beyond 10-fold in the case of PARP12. This allows us to measure their activity using a homogeneous NAD+ conversion assay, facilitating its automation to lower the assay volume and costs. The approach will enable the discovery of more potent compounds due to increased assay sensitivity.</p>","PeriodicalId":54543,"journal":{"name":"Protein Engineering Design & Selection","volume":"35 ","pages":""},"PeriodicalIF":2.6,"publicationDate":"2022-02-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9574550/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10732628","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"生物学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Correction to: Protease-stable DARPins as promising oral therapeutics. 更正:蛋白酶稳定的DARPins作为有前途的口服治疗药物。
IF 2.4 4区 生物学
Protein Engineering Design & Selection Pub Date : 2022-02-17 DOI: 10.1093/protein/gzac003
Rudo A Simeon, Yu Zeng, Vikas Chonira, Andrea Martinez Aguirre, Mauricio Lasagna, Marko Baloh, Joseph A Sorg, Cecilia Tommos, Zhilei Chen
{"title":"Correction to: Protease-stable DARPins as promising oral therapeutics.","authors":"Rudo A Simeon,&nbsp;Yu Zeng,&nbsp;Vikas Chonira,&nbsp;Andrea Martinez Aguirre,&nbsp;Mauricio Lasagna,&nbsp;Marko Baloh,&nbsp;Joseph A Sorg,&nbsp;Cecilia Tommos,&nbsp;Zhilei Chen","doi":"10.1093/protein/gzac003","DOIUrl":"https://doi.org/10.1093/protein/gzac003","url":null,"abstract":"","PeriodicalId":54543,"journal":{"name":"Protein Engineering Design & Selection","volume":"35 ","pages":""},"PeriodicalIF":2.4,"publicationDate":"2022-02-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9081868/pdf/gzac003.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10031816","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"生物学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Bispecific antibodies-effects of point mutations on CH3-CH3 interface stability. 点突变对 CH3-CH3 界面稳定性的影响。
IF 2.6 4区 生物学
Protein Engineering Design & Selection Pub Date : 2022-02-17 DOI: 10.1093/protein/gzac012
Nancy D Pomarici, Monica L Fernández-Quintero, Patrick K Quoika, Franz Waibl, Alexander Bujotzek, Guy Georges, Klaus R Liedl
{"title":"Bispecific antibodies-effects of point mutations on CH3-CH3 interface stability.","authors":"Nancy D Pomarici, Monica L Fernández-Quintero, Patrick K Quoika, Franz Waibl, Alexander Bujotzek, Guy Georges, Klaus R Liedl","doi":"10.1093/protein/gzac012","DOIUrl":"10.1093/protein/gzac012","url":null,"abstract":"<p><p>A new format of therapeutic proteins is bispecific antibodies, in which two different heavy chains heterodimerize to obtain two different binding sites. Therefore, it is crucial to understand and optimize the third constant domain (CH3-CH3) interface to favor heterodimerization over homodimerization, and to preserve the physicochemical properties, as thermal stability. Here, we use molecular dynamics simulations to investigate the dissociation process of 19 CH3-CH3 crystal structures that differ from each other in few point mutations. We describe the dissociation of the dimeric interface as a two-steps mechanism. As confirmed by a Markov state model, apart from the bound and the dissociated state, we observe an additional intermediate state, which corresponds to an encounter complex. The analysis of the interdomain contacts reveals key residues that stabilize the interface. We expect that our results will improve the understanding of the CH3-CH3 interface interactions and thus advance the developability and design of new antibodies formats.</p>","PeriodicalId":54543,"journal":{"name":"Protein Engineering Design & Selection","volume":"35 ","pages":""},"PeriodicalIF":2.6,"publicationDate":"2022-02-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9741699/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10353046","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"生物学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Stabilization of the SARS-CoV-2 receptor binding domain by protein core redesign and deep mutational scanning. 通过蛋白质核心重新设计和深度突变扫描稳定 SARS-CoV-2 受体结合域。
IF 2.6 4区 生物学
Protein Engineering Design & Selection Pub Date : 2022-02-17 DOI: 10.1093/protein/gzac002
Alison C Leonard, Jonathan J Weinstein, Paul J Steiner, Annette H Erbse, Sarel J Fleishman, Timothy A Whitehead
{"title":"Stabilization of the SARS-CoV-2 receptor binding domain by protein core redesign and deep mutational scanning.","authors":"Alison C Leonard, Jonathan J Weinstein, Paul J Steiner, Annette H Erbse, Sarel J Fleishman, Timothy A Whitehead","doi":"10.1093/protein/gzac002","DOIUrl":"10.1093/protein/gzac002","url":null,"abstract":"<p><p>Stabilizing antigenic proteins as vaccine immunogens or diagnostic reagents is a stringent case of protein engineering and design as the exterior surface must maintain recognition by receptor(s) and antigen-specific antibodies at multiple distinct epitopes. This is a challenge, as stability enhancing mutations must be focused on the protein core, whereas successful computational stabilization algorithms typically select mutations at solvent-facing positions. In this study, we report the stabilization of SARS-CoV-2 Wuhan Hu-1 Spike receptor binding domain using a combination of deep mutational scanning and computational design, including the FuncLib algorithm. Our most successful design encodes I358F, Y365W, T430I, and I513L receptor binding domain mutations, maintains recognition by the receptor ACE2 and a panel of different anti-receptor binding domain monoclonal antibodies, is between 1 and 2°C more thermally stable than the original receptor binding domain using a thermal shift assay, and is less proteolytically sensitive to chymotrypsin and thermolysin than the original receptor binding domain. Our approach could be applied to the computational stabilization of a wide range of proteins without requiring detailed knowledge of active sites or binding epitopes. We envision that this strategy may be particularly powerful for cases when there are multiple or unknown binding sites.</p>","PeriodicalId":54543,"journal":{"name":"Protein Engineering Design & Selection","volume":"35 ","pages":""},"PeriodicalIF":2.6,"publicationDate":"2022-02-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9077414/pdf/gzac002.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9166459","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"生物学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
A multivalent antibody assembled from different building blocks using tag/catcher systems: a case study. 使用标签/捕集器系统从不同构建块组装的多价抗体:一个案例研究。
IF 2.4 4区 生物学
Protein Engineering Design & Selection Pub Date : 2022-02-17 DOI: 10.1093/protein/gzac014
Christof Schindler, Christine Faust, Hanno Sjuts, Christian Lange, Jennifer Kühn, Werner Dittrich, Wulf Dirk Leuschner, Werner Schiebler, Joachim Hofmann, Ercole Rao, Thomas Langer
{"title":"A multivalent antibody assembled from different building blocks using tag/catcher systems: a case study.","authors":"Christof Schindler,&nbsp;Christine Faust,&nbsp;Hanno Sjuts,&nbsp;Christian Lange,&nbsp;Jennifer Kühn,&nbsp;Werner Dittrich,&nbsp;Wulf Dirk Leuschner,&nbsp;Werner Schiebler,&nbsp;Joachim Hofmann,&nbsp;Ercole Rao,&nbsp;Thomas Langer","doi":"10.1093/protein/gzac014","DOIUrl":"https://doi.org/10.1093/protein/gzac014","url":null,"abstract":"<p><p>The field of therapeutic antibodies and, especially bi- or multispecific antibodies, is growing rapidly. Especially for treating cancers, multispecific antibodies are very promising, as there are multiple pathways involved and multispecific antibodies offer the possibility to interfere at two or more sites. Besides being used as therapeutic, multispecific antibodies can be helpful tools in basic research. However, the design and choice of the most appropriate multispecific antibody format are far from trivial. The generation of multispecific antibodies starts with the generation of antibodies directed against the desired targets and then combining the different antigen-binding sites in one molecule. This is a time-consuming and laborious approach since the most suitable geometry cannot be predicted. The SpyTag technology is based on a split-protein system, where a small peptide of said protein, the SpyTag, can bind to the remaining protein, the SpyCatcher. An irreversible isopeptide bond between the SpyTag and the SpyCatcher is formed. A related Tag-Catcher system is the SnoopTag-SnoopCatcher. These systems offer the opportunity to separately produce proteins fused to the tag-peptides and to the catcher-domains and assemble them in vitro. Our goal was to design and produce different antibody fragments, Fab domains and Fc-containing domains, with different tags and/or catchers as building blocks for the assembly of different multivalent antibodies. We have shown that large multivalent antibodies consisting of up to seven building blocks can be prepared. Binding experiments demonstrated that all binding sites in such a large molecule retained their accessibility to their corresponding antigens.</p>","PeriodicalId":54543,"journal":{"name":"Protein Engineering Design & Selection","volume":"35 ","pages":""},"PeriodicalIF":2.4,"publicationDate":"2022-02-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9226656","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"生物学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Structure-based engineering of minimal proline dehydrogenase domains for inhibitor discovery. 基于结构工程的最小脯氨酸脱氢酶结构域抑制剂发现。
IF 2.4 4区 生物学
Protein Engineering Design & Selection Pub Date : 2022-02-17 DOI: 10.1093/protein/gzac016
Alexandra N Bogner, Juan Ji, John J Tanner
{"title":"Structure-based engineering of minimal proline dehydrogenase domains for inhibitor discovery.","authors":"Alexandra N Bogner, Juan Ji, John J Tanner","doi":"10.1093/protein/gzac016","DOIUrl":"10.1093/protein/gzac016","url":null,"abstract":"<p><p>Proline dehydrogenase (PRODH) catalyzes the FAD-dependent oxidation of l-proline to Δ1-pyrroline-5-carboxylate and is a target for inhibitor discovery because of its importance in cancer cell metabolism. Because human PRODH is challenging to purify, the PRODH domains of the bacterial bifunctional enzyme proline utilization A (PutA) have been used for inhibitor development. These systems have limitations due to large polypeptide chain length, conformational flexibility and the presence of domains unrelated to PRODH activity. Herein, we report the engineering of minimal PRODH domains for inhibitor discovery. The best designs contain one-third of the 1233-residue PutA from Sinorhizobium meliloti and include a linker that replaces the PutA α-domain. The minimal PRODHs exhibit near wild-type enzymatic activity and are susceptible to known inhibitors and inactivators. Crystal structures of minimal PRODHs inhibited by S-(-)-tetrahydro-2-furoic acid and 2-(furan-2-yl)acetic acid were determined at 1.23 and 1.72 Å resolution. Minimal PRODHs should be useful in chemical probe discovery.</p>","PeriodicalId":54543,"journal":{"name":"Protein Engineering Design & Selection","volume":"35 ","pages":""},"PeriodicalIF":2.4,"publicationDate":"2022-02-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9801229/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10670094","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"生物学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
相关产品
×
本文献相关产品
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信